{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:47:22Z","timestamp":1770421642637,"version":"3.49.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>More than 90% of patients developing heart failure (HF) have an epidemiological background of hypertension. The most frequent concomitant conditions are type 2 diabetes mellitus, obesity, atrial fibrillation, and coronary disease, all disorders\/diseases closely related to hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>HF outcome research focuses on decreasing mortality and preventing hospitalization for worsening HF syndrome. All drugs that decrease these HF endpoints lower blood pressure. Current drug treatments for HF are (i) angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor neprilysin inhibitors, (ii) selected beta-blockers, (iii) steroidal and nonsteroidal mineralocorticoid receptor antagonists, and (iv) sodium-glucose cotransporter 2 inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>For various reasons, these drug treatments were first studied in HF patients with a reduced ejection fraction (HFrEF). However, subsequently, they have been investigated and, as we see it, documented as beneficial in HF patients with a preserved left ventricular ejection fraction (LVEF, HFpEF) and mostly hypertensive etiology, with effect estimates assessed partly on top of background treatment with the drugs already proven effective in HFrEF. Additionally, diuretics are given on symptomatic indications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Considering the totality of evidence and the overall need for antihypertensive treatment and\/or treatment of hypertensive complications in almost all HF patients, the principal drug treatment of HF appears to be the same regardless of LVEF. Rather than LVEF-guided treatment of HF, treatment of HF should be directed by symptoms (related to the level of fluid retention), signs (tachycardia), severity (NYHA functional class), and concomitant diseases and conditions. All HF patients should be given all the drug classes mentioned above if well tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpad073","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T12:35:40Z","timestamp":1691498140000},"page":"1-14","source":"Crossref","is-referenced-by-count":9,"title":["What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence"],"prefix":"10.1093","volume":"37","author":[{"given":"Kaja","family":"Sevre","sequence":"first","affiliation":[{"name":"University of Oslo, Medical School and Institute of Clinical Medicine , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Rist","sequence":"additional","affiliation":[{"name":"University of Oslo, Medical School and Institute of Clinical Medicine , Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5861-1478","authenticated-orcid":false,"given":"Kristian","family":"Wachtell","sequence":"additional","affiliation":[{"name":"Weill-Cornell Medicine, Division of Cardiology , New York City, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B","family":"Devereux","sequence":"additional","affiliation":[{"name":"Weill-Cornell Medicine, Division of Cardiology , New York City, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard P","family":"Aurigemma","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, UMassChan School of Medicine , Worcester, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-9954","authenticated-orcid":false,"given":"Otto A","family":"Smiseth","sequence":"additional","affiliation":[{"name":"University of Oslo, Institute for Surgical Research and Department of Cardiology , Rikshospitalet, Oslo , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-0272","authenticated-orcid":false,"given":"Sverre E","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"University of Oslo, Medical School and Institute of Clinical Medicine , Oslo , Norway"},{"name":"Departments of Cardiology and Nephrology, Ullevaal Hospital , Oslo , Norway"},{"name":"University of Michigan, Division of Cardiovascular Medicine , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stevo","family":"Julius","sequence":"additional","affiliation":[{"name":"University of Michigan, Division of Cardiovascular Medicine , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Division of Cardiovascular Medicine , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-8487","authenticated-orcid":false,"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[{"name":"Faculty of Biology and Medicine, University of Lausanne , Lausanne , Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-211X","authenticated-orcid":false,"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-2599","authenticated-orcid":false,"given":"Suzanne","family":"Oparil","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Vascular Biology and Hypertension Program, Department of Medicine , Birmingham, Alabama , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"University of Milan-Bicocca , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universite de Lorraine, Inserm, Centre d\u2019Investigations Cliniques-1433 and F-CRIN INI CRCT , Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2023121606073667600_CIT0001","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0002","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2023121606073667600_CIT0003","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"2023121606073667600_CIT0004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0006","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0007","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ejhf.2576","article-title":"Left ventricular ejection fraction as the primary heart failure phenotyping parameter","volume":"24","author":"Lund","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023121606073667600_CIT0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12574-017-0364-2","article-title":"Evaluation of left ventricular diastolic function: state of the art after 35 years with Doppler assessment","volume":"16","author":"Smiseth","year":"2018","journal-title":"J Echocardiogr"},{"key":"2023121606073667600_CIT0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2023121606073667600_CIT0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2023121606073667600_CIT0011","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0012","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0013","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0014","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0016","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen","year":"2020","journal-title":"Hypertension"},{"key":"2023121606073667600_CIT0019","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"2023121606073667600_CIT0020","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0021","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccl.2022.06.004","article-title":"Pharmacologic therapy for heart failure with preserved ejection fraction","volume":"40","author":"Peters","year":"2022","journal-title":"Cardiol Clin"},{"key":"2023121606073667600_CIT0023","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12265-022-10324-y","article-title":"Heart failure with preserved ejection fraction: pathogenesis, diagnosis, exercise, and medical therapies","volume":"16","author":"Zhan","year":"2022","journal-title":"J Cardiovasc Trans Res"},{"key":"2023121606073667600_CIT0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HCO.0000000000000981","article-title":"New concepts in heart failure with preserved ejection fraction and hypertension","volume":"37","author":"Joury","year":"2022","journal-title":"Curr Opin Cardiol"},{"key":"2023121606073667600_CIT0025","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.3390\/jcm11133706","article-title":"Reshaping treatment of heart failure with preserved ejection fraction","volume":"11","author":"Karamichalakis","year":"2022","journal-title":"J Clin Med"},{"key":"2023121606073667600_CIT0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","article-title":"Heart failure with preserved ejection fraction: mechanisms and treatment strategies","volume":"73","author":"Omote","year":"2022","journal-title":"Annu Rev Med"},{"key":"2023121606073667600_CIT0027","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"2023121606073667600_CIT0028","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"2023121606073667600_CIT0029","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2023121606073667600_CIT0031","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00392-020-01632-x","article-title":"Covariate adjusted reanalysis of the I-Preserve trial","volume":"109","author":"Ferreira","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2023121606073667600_CIT0032","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10582452.2012.741765","article-title":"Angiotensin receptor\u2014neprilysin inhibition (ARNI)\u2014a novel therapeutic concept for management of hypertension and heart failure","volume":"21","author":"Kjeldsen","year":"2012","journal-title":"Blood Press"},{"key":"2023121606073667600_CIT0033","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","volume":"6","author":"von Lueder","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2023121606073667600_CIT0034","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"2023121606073667600_CIT0035","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0036","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2023121606073667600_CIT0037","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF Randomized Clinical Trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"key":"2023121606073667600_CIT0038","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ehjacc\/zuac144","article-title":"Torsemide comparison with furosemide for management of heart failure (TRANSFORM-HF) trial","volume":"11","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2023121606073667600_CIT0039","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension\u2013cardiovascular events","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/hrt.2010.207365","article-title":"\u03b2-Blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure","volume":"97","author":"Ambrosio","year":"2011","journal-title":"Heart"},{"key":"2023121606073667600_CIT0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"2023121606073667600_CIT0043","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0044","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/cvr\/cvab222","article-title":"Central and peripheral sympathetic activation in heart failure","volume":"118","author":"Grassi","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023121606073667600_CIT0045","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/01.hjh.0000239288.10013.04","article-title":"N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy","volume":"24","author":"Olsen","year":"2006","journal-title":"J Hypertens"},{"key":"2023121606073667600_CIT0046"},{"key":"2023121606073667600_CIT0047","author":"Pieske","year":"2021"},{"key":"2023121606073667600_CIT0048","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0049","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0050","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0051"},{"key":"2023121606073667600_CIT0052","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0053","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0054","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023121606073667600_CIT0056","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 Inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0057","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0058","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2023121606073667600_CIT0059","first-page":"CD012721","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","volume":"5","author":"Martin","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2023121606073667600_CIT0060","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000484","article-title":"Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and network meta-analysis","author":"Sreenivasan","year":"2022","journal-title":"Cardiol Rev"},{"key":"2023121606073667600_CIT0061","doi-asserted-by":"crossref","first-page":"e2231963","DOI":"10.1001\/jamanetworkopen.2022.31963","article-title":"Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis","volume":"5","author":"Xiang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023121606073667600_CIT0062","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/CIRCULATIONAHA.122.062052","article-title":"What\u2019s EF got to do, got to do with it","volume":"146","author":"Kass","year":"2022","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0063","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.122.062022","article-title":"DELIVERing therapeutic efficacy across the ejection fraction spectrum of heart failure","volume":"146","author":"Lam","year":"2022","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0064","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"2023121606073667600_CIT0065","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations","volume":"65","author":"Asgar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023121606073667600_CIT0066","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/HJH.0b013e328339f943","article-title":"In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study","volume":"28","author":"Wachtell","year":"2010","journal-title":"J Hypertens"},{"key":"2023121606073667600_CIT0067","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.000045","article-title":"Natural history of left ventricular ejection fraction in patients with heart failure","volume":"6","author":"Clarke","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2023121606073667600_CIT0068","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jchf.2017.12.014","article-title":"Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF","volume":"6","author":"Savarese","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2023121606073667600_CIT0069","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.2439","article-title":"Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF","volume":"24","author":"Pab\u00f3n","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2023121606073667600_CIT0070","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2023121606073667600_CIT0071","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cccn.2005.05.021","article-title":"Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: comparison with brain natriuretic peptide (BNP)","volume":"361","author":"Chenevier-Gobeaux","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2023121606073667600_CIT0072","doi-asserted-by":"crossref","first-page":"e012336","DOI":"10.1161\/JAHA.119.012336","article-title":"Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"8","author":"Bansal","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2023121606073667600_CIT0073","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0002-9149(79)90235-2","article-title":"Ventricular function and coronary hemodynamics in hypertensive heart disease","volume":"44","author":"Strauer","year":"1979","journal-title":"Am J Cardiol"},{"key":"2023121606073667600_CIT0074","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/HJH.0b013e3283516499","article-title":"Impact of lower achieved blood pressure on outcomes in hypertensive patients","volume":"30","author":"Okin","year":"2012","journal-title":"J Hypertens"},{"key":"2023121606073667600_CIT0075","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/HYPERTENSIONAHA.123.21454","article-title":"Middle-aged and older patients with left ventricular hypertrophy: higher mortality with drug treated blood pressure below 130\/80 mmHg","volume":"80","author":"Heimark","year":"2023","journal-title":"Hypertension"},{"key":"2023121606073667600_CIT0076","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","article-title":"Diabetes, cardiovascular disease and the microcirculation","volume":"17","author":"Strain","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2023121606073667600_CIT0077","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"2023121606073667600_CIT0078","doi-asserted-by":"crossref","first-page":"e001293","DOI":"10.1161\/JAHA.114.001293","article-title":"Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction","volume":"3","author":"van Empel","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2023121606073667600_CIT0079","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023121606073667600_CIT0080","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpad073\/51273283\/hpad073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/1\/1\/54533485\/hpad073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/37\/1\/1\/54533485\/hpad073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T06:08:26Z","timestamp":1702706906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/37\/1\/1\/7238777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpad073","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,8,8]]}}}